Lani M. Alison, BSN, MS, HCQ, PCMH, CCE, vice president of Clinical Affairs, Regional Cancer Care Associates, explains how the implementation of the Oncology Care Model (OCM) allowed practices to better integrate palliative care.
Lani M. Alison, BSN, MS, HCQ, PCMH, CCE, vice president of Clinical Affairs, Regional Cancer Care Associates, explains how the implementation of the Oncology Care Model (OCM) allowed practices to better integrate palliative care.
Transcript
How has the implementation of the OCM allowed practices to better integrate palliative care, and what impact does that have?
The practice transformation plan, which is really the heart of the Oncology Care Model, requires that we provide a patient a 13-point institute of medicine care plan, and one of those is either survivorship care planning for patients whose trajectory is survivorship and end of life, and part of that is really when the patient actually understands that the cancer has progressed and then the conversation starts. RCCA’s approach to this is it doesn’t matter, as long as you have spoken to the patient about cancer therapy. It may not be the metastatic type.
But I think in any chronic disease, not just cancer, we should really have a conversation with the patient about advanced care planning. Who is their healthcare proxy? Because that is pretty much a non-threatening or not very uncomfortable to talk about. In my family, we have already spoken about that. So, the conversation is a little bit lighter rather than a patient who is already in palliative care or you’re going to tell the patient we’re going to start you on palliative care and they don’t even have a healthcare proxy. It’s a big challenge.
OCM has really paved the way. We use it as the standard of care for cancer because it requires that. In the OCM model, it is very difficult to succeed if you don’t have end of life, palliative care that includes palliative care and hospice and actually bereavement as part of its services. We have to really think about the patient’s outcomes, which include financial outcomes for the patients, as well as the total patient experience. It has to be part of that. If you start asking about their healthcare proxy, when the time comes, you just move along the conversation and say, “Ok, Suzy is you’re proxy, now we’re going to think about your cancer has progressed, what is next?” So, then if the patient is in pain, we’re going to talk about palliation, so you really are informing the caregivers of the patient what could be next. So, it’s not going to be such an uncomfortable conversation anymore.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More
Navigating the Mental Health Challenges of Cancer Diagnosis, Treatment, and Survivorship
March 12th 2024Stress has potential links to worse outcomes in cancer, such as decreased quality of life and greater risks of disease progression and metastasis. There is a complex mix of emotions patients with cancer experience.
Read More